HPV-Associated oropharyngeal cancer: Changes in epidemiological profile and prognostic implications

Human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma has altered the epidemiology and prognostic interpretation of head and neck cancer. This narrative critical review examines changes in incidence and demographic distribution, the validity of HPV-related tumor classification, and the implications of viral status for survival and treatment decisions. Literature indexed in PubMed/MEDLINE through 2026 was examined alongside professional guidelines and institutional cancer-prevention resources. Population-based studies document a marked increase in HPV-associated oropharyngeal cancer in several high-income settings, with an increasingly important burden among older men, while estimates remain heterogeneous across regions. HPV-positive tumors generally have more favorable survival than HPV-negative tumors, but smoking exposure, disease extent, and discordance between p16 and HPV-specific tests modify this advantage. Staging revisions acknowledge the distinct disease phenotype, including refinements introduced in 2026. Randomized trials demonstrate that favorable prognosis cannot justify indiscriminate treatment reduction, although selected postoperative de-intensification approaches are promising. Vaccination reduces vaccine-type oral HPV infection, whereas an effect on incident oropharyngeal cancer will require longer observation. Prognostic assessment should integrate viral attribution, anatomical stage, patient characteristics, treatment quality, and long-term functional outcomes.